The Centers for Medicare & Medicaid Services has proposed cuts to 340B drug payment rates as part of a broader effort to lower Medicare costs, while HRSA separately reported that 340B program sales hit $100 billion in calendar year 2025. The 340B program allows safety-net hospitals to buy drugs at steep discounts and bill Medicare at higher rates — a spread that has become a major revenue line for large hospital systems.
Healthcare & FDA
CMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivals
A federal proposal to cut what Medicare pays hospitals under the 340B drug discount program hits hospital systems hardest — and the FTC's Caremark settlement adds pressure on the other side.
Hospitals built entire revenue lines around the 340B spread. CMS is proposing to shrink that spread — and the hospital stocks most dependent on it have the least room to absorb the hit.
Who cashes in: Specialty pharmacy operators and PBMs that compete with hospital outpatient pharmacies stand to gain if hospital 340B economics weaken and patient volume shifts. CVS Health CVS — which just settled an FTC antitrust case over its Caremark PBM — and Cigna's Express Scripts (CI) benefit if hospitals lose pricing advantage in outpatient drug dispensing. Smaller independent pharmacies, which the FTC settlement explicitly aims to help, could see volume gains, but there are no clean pure-play public tickers there.
Who's exposed: Large nonprofit and for-profit hospital systems that have built revenue models around 340B spreads face the most direct hit. HCA Healthcare HCA, Tenet Healthcare THC, and Universal Health Services UHS all operate significant outpatient pharmacy and infusion operations where 340B revenue is material. Community Health Systems CYH, which operates in lower-income markets where 340B eligibility is concentrated, is particularly exposed. The cuts are proposed, not final — but the direction of travel is clear and has been for two years.
Watch the final CMS rule, expected later this year. If the cuts survive the comment period without significant rollback, hospital stocks with high 340B exposure will reprice. HCA and Tenet have enough scale to absorb it; CYH has less cushion.
Source: original report ↗
Free alerts
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Knowing who cashed in is only half the trade.
Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.
Get the edge · $40/moJoin the readers who get there before the financial press. Cancel anytime, one click.